

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
29 December 2004 (29.12.2004)

PCT

(10) International Publication Number
WO 2004/113571 A2

(51) International Patent Classification⁷:

C12Q 1/68

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:

PCT/IB2004/002394

(22) International Filing Date: 25 June 2004 (25.06.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/482,595

26 June 2003 (26.06.2003) US

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): EXON-HIT THERAPEUTICS SA [FR/FR]; 26, rue Brunel, F-75017 Paris (FR).

Declaration under Rule 4.17:

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

- (72) Inventors; and
(75) Inventors/Applicants (*for US only*): EINSTEIN, Richard [US/US]; 12421 Galesville Dr., Gaithersburg, MD 20878 (US). MCGOWAN, Kevin, M. [US/US]; 15132 Winesap Drive, N. Potomac, MD 20878 (US). PANDO, Matthew, P. [US/US]; 2004 N. Cleveland Street, Arlington, VA 22201 (US).
(74) Agents: BECKER, Philippe et al.; Becker & Associés, 35 rue des Mathurins, F-75008 Paris (FR).

WO 2004/113571 A2

(54) Title: PROSTATE SPECIFIC GENES AND THE USE THEREOF AS TARGETS FOR PROSTATE CANCER THERAPY AND DIAGNOSIS

(57) Abstract: Genes that are upregulated in human prostate tumor tissues and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of prostate cancer.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
29 December 2004 (29.12.2004)

PCT

(10) International Publication Number
WO 2004/113571 A3

- (51) International Patent Classification⁷: C12Q 1/68
- (21) International Application Number: PCT/IB2004/002394
- (22) International Filing Date: 25 June 2004 (25.06.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/482,595 26 June 2003 (26.06.2003) US
- (71) Applicant (for all designated States except US): EXON-HIT THERAPEUTICS SA [FR/FR]; 26, rue Brunel, F-75017 Paris (FR).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): EINSTEIN, Richard [US/US]; 12421 Galesville Dr., Gaithersburg, MD 20878 (US). MCGOWAN, Kevin, M. [US/US]; 15132 Winesap Drive, N. Potomac, MD 20878 (US). PANDO, Matthew, P. [US/US]; 2004 N. Cleveland Street, Arlington, VA 22201 (US).
- (74) Agents: BECKER, Philippe et al.; Becker & Associés, 35 rue des Mathurins, F-75008 Paris (FR).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

28 April 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROSTATE SPECIFIC GENES AND THE USE THEREOF AS TARGETS FOR PROSTATE CANCER THERAPY AND DIAGNOSIS

(57) Abstract: Genes that are upregulated in human prostate tumor tissues and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of prostate cancer.